|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2000-1-18
|
|
pubmed:abstractText |
To evaluate the toxicity and efficacy of a 4-day regimen of docetaxel, cisplatin, fluorouracil, and leucovorin (TPFL4) in patients with locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:AdanNN,
pubmed-author:AmreinPP,
pubmed-author:BartonJJ,
pubmed-author:ColevasA DAD,
pubmed-author:CostelloRR,
pubmed-author:FriedM PMP,
pubmed-author:GomolinH IHI,
pubmed-author:LambCC,
pubmed-author:NixonAA,
pubmed-author:NorrisC MCM,
pubmed-author:PosnerM RMR,
pubmed-author:ReadRR,
pubmed-author:TishlerR BRB
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3503-11
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10550148-Adult,
pubmed-meshheading:10550148-Aged,
pubmed-meshheading:10550148-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10550148-Carcinoma, Squamous Cell,
pubmed-meshheading:10550148-Cisplatin,
pubmed-meshheading:10550148-Combined Modality Therapy,
pubmed-meshheading:10550148-Dose-Response Relationship, Drug,
pubmed-meshheading:10550148-Fluorouracil,
pubmed-meshheading:10550148-Head and Neck Neoplasms,
pubmed-meshheading:10550148-Humans,
pubmed-meshheading:10550148-Leucovorin,
pubmed-meshheading:10550148-Middle Aged,
pubmed-meshheading:10550148-Mouth Mucosa,
pubmed-meshheading:10550148-Nausea,
pubmed-meshheading:10550148-Paclitaxel,
pubmed-meshheading:10550148-Stomatitis,
pubmed-meshheading:10550148-Taxoids
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck.
|
|
pubmed:affiliation |
Head and Neck Oncology Program and Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA 02115, USA. alexandervcolevas@dfci.harvard.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
